About EDGAR Online | Login
 
The following is an excerpt from a 10-Q SEC Filing, filed by PARADIGM GENETICS INC on 5/17/2004.
Next Section Next Section Previous Section Previous Section
ICORIA, INC. - 10-Q - 20040517 - INCOME_STATEMENT

PARADIGM GENETICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

    

Three Months

Ended March 31,


 
     2004

    2003

 

Revenues:

                

Commercial partnerships and government contracts

   $ 4,364,619     $ 3,838,844  

Grant revenues

     523,439       228,339  
    


 


Total revenues

     4,888,058       4,067,183  
    


 


Operating expenses:

                

Research and development (includes $1,119 and $135,603 of stock-based compensation expense for the three months ended March 31, 2004 and 2003, respectively)

     6,633,777       5,849,932  

Selling, general and administrative (includes $687 and $149,493 of stock-based compensation expense for the three months ended March 31, 2004 and 2003, respectively)

     1,886,187       2,234,114  
    


 


Total operating expenses

     8,519,964       8,084,046  
    


 


Loss from operations

     (3,631,906 )     (4,016,863 )
    


 


Other income (expense):

                

Interest income

     60,239       108,665  

Interest expense

     (122,671 )     (233,266 )
    


 


Other income (expense), net

     (62,432 )     (124,601 )
    


 


Loss from continuing operations

     (3,694,338 )     (4,141,464 )

Discontinued operations:

Gain (loss) from discontinued operations

     22,725       24,669  
    


 


Net loss

   $ (3,671,613 )   $ (4,116,795 )
    


 


Net loss per common share-basic and diluted:

                

Loss per share from continuing operations

   $ (0.11 )   $ (0.13 )

Loss per share from discontinued operations

     —         —    
    


 


Net loss per common share

   $ (0.11 )   $ (0.13 )
    


 


Weighted average common shares outstanding – basic and diluted

     33,425,044       32,040,876